ACOX3

Across TCGA pan-cancer cohorts, ACOX3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACOX3 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACOX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACOX3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where ACOX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.252	0.459	.006	21	view →
LUAD	DFS	Quartile	II,III,IV	0.225	0.706	.004	17	view →
HNSC	DFS	Quartile	IV	0.863	0.515	.010	14	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
CCRCC	DFS	Tertile	III,IV	0.185	0.978	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACOX3–PDAC (DFS)

Open the PDAC breakdown →